1
|
Qi Y, Zhou N, Jiang Q, Wang Z, Zhang Y, Li B, Xu W, Liu J, Wang Z, Zhu L. Dose-Dependent Variation of Synchronous Metabolites and Modules in a Yin/Yang Transformation Model of Appointed Ischemia Metabolic Networks. Front Neurosci 2021; 15:645185. [PMID: 34531713 PMCID: PMC8439200 DOI: 10.3389/fnins.2021.645185] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Accepted: 07/22/2021] [Indexed: 01/26/2023] Open
Abstract
Aim Chinese medicine Danhong injection (DHI) is an effective pharmaceutical preparation for treating cerebral infarction. Our previous study shows that DHI can remarkably reduce the ischemic stroke-induced infarct volume in a dose-dependent manner, but the pharmacological mechanism of the DHI dose-dependent relationship is not clear. Therefore, the dose-dependent efficacy of DHI on cerebral ischemia and the underlying mechanisms were further investigated in this study. Methods A middle cerebral artery occlusion (MCAO) model was established and the rats were randomly divided into six groups: sham, vehicle, DHI dose-1, DHI dose-2, DHI dose-3, and DHI dose-4. Forty-one metabolites in serum were selected as candidate biomarkers of efficacy phenotypes by the Agilent 1290 rapid-resolution liquid chromatography system coupled with the Agilent 6550 Q-TOF MS system. Then, the metabolic networks in each group were constructed using the Weighted Correlation Network analysis (WGCNA). Moreover, the Yang and Yin transformation of six patterns (which are defined by up- and downregulation of metabolites) and synchronous modules divided from a synchronous network were used to dynamically analyze the mechanism of the drug’s effectiveness. Results The neuroprotective effect of DHI has shown a dose-dependent manner, and the high-dose group (DH3 and DH4) effect is better. The entropy of the metabolic network and the Yin/Yang index both showed a consistent dose–response relationship. Seven dose-sensitive metabolites maintained constant inverse upregulation or downregulation in the four dose groups. Three synchronous modules for the DH1–DH4 full-course network were identified. Glycine, N-acetyl-L-glutamate, and tetrahydrofolate as a new emerging module appeared in DH2/DH3 and enriched in glutamine and glutamate metabolism-related pathways. Conclusion This study takes the DHI metabolic network as an example to provide a new method for the discovery of multiple targets related to pharmacological effects. Our results show that the three conservative allosteric module nodes, taurine, L-tyrosine, and L-leucine, may be one of the basic mechanisms of DHI in the treatment of cerebral infarction, and the other three new emerging module nodes glyoxylate, L-glutamate, and L-valine may participate in the glutamine and glutamate metabolism pathway to improve the efficacy of DHI.
Collapse
Affiliation(s)
- Yifei Qi
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.,Xiyuan Hospital, Institute of Geriatrics, China Academy of Chinese Medical Sciences, Beijing, China
| | - Niwen Zhou
- Center for Statistics and Data Science, Beijing Normal University at Zhuhai, Zhuhai, China
| | - Qing Jiang
- Center for Statistics and Data Science, Beijing Normal University at Zhuhai, Zhuhai, China
| | - Zhi Wang
- Global Business Services, International Business Machines Corporation, Shanghai, China
| | - Yingying Zhang
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
| | - Bing Li
- Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China
| | - Wenjuan Xu
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China
| | - Jun Liu
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
| | - Zhong Wang
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
| | - Lixing Zhu
- Center for Statistics and Data Science, Beijing Normal University at Zhuhai, Zhuhai, China.,Department of Mathematics, Hong Kong Baptist University, Hong Kong, China
| |
Collapse
|
2
|
Gogoi D, Ramani S, Bhartari S, Chattopadhyay P, Mukherjee AK. Characterization of active anticoagulant fraction and a fibrin(ogen)olytic serine protease from leaves of Clerodendrum colebrookianum, a traditional ethno-medicinal plant used to reduce hypertension. JOURNAL OF ETHNOPHARMACOLOGY 2019; 243:112099. [PMID: 31326559 DOI: 10.1016/j.jep.2019.112099] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Revised: 05/21/2019] [Accepted: 07/16/2019] [Indexed: 06/10/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Cardiovascular diseases are the major cause of mortality and morbidity, causing over 17.9 million deaths a year worldwide. Currently used therapy is often having side effects and expensive, dietary interventions and alternative medicines are required. Clerodendrum colebrookianum has been used to treat cardiac hypertension but anticoagulant potency was not evaluated. AIM OF THE STUDY To characterize an active anticoagulant fraction (AAFCC) and a 30 kDa fibrin(ogen)olytic serine protease (clerofibrase) isolated from aqueous leave extract of C. colebrookianum. MATERIALS AND METHODS AAFCC/clerofibrase was subjected to extensive biochemical and pharmacological characterization including LC-MS/MS, amino acid compositional and GC-MS analyses. Interaction between clerofibrase with fibrinogen was studied by spectrofluorometric analysis. In vitro thrombolytic, antiplatelet and cytotoxicity assay were performed. In vivo toxicity, anticoagulant, defibrinogen and antithrombotic activities were determined on Swiss albino mice. RESULTS The in vitro anticoagulant activity of AAFCC was found to be superior to heparin and clerofibrase and comparable to Nattokinase and warfarin. The proteomics and amino acid composition analyses suggest that clerofibrase is a previously uncharacterized novel plant protease capable of degrading the -αβ chains of fibrinogen/fibrin. AAFCC/clerofibrase exerts their anticoagulant action via fibrinogenolytic activity and partially by antiplatelet activity albeit they have no effect on thrombin and FXa inhibition. The spectrofluorometric analysis revealed the binding of clerofibrase to fibrinogen but not to thrombin and FXa. The phytochemical constituents and bioactive components of AAFCC were characterized by biochemical, and GC-MS analyses. The AAFCC and clerofibrase inhibited collagen/ADP-induced mammalian platelet aggregation, showed in vitro thrombolytic activity, and non-cytotoxic to mammalian cells. The AAFCC showed and dose-dependent in vivo plasma defibrinogenating and anticoagulant activities and inhibited k-carrageen-induced thrombus formation in the tails of mice. CONCLUSION The potent in vivo anticoagulant and antithrombotic effects of AAFCC suggests its pharmacological significance as herbal anticoagulant drug for the prevention and/or treatment of hyperfibrinogenemia- and thrombosis associated cardiovascular disorders.
Collapse
Affiliation(s)
- Debananda Gogoi
- Microbial Biotechnology and Protein Research Laboratory, Department of Molecular Biology and Biotechnology, School of Sciences, Tezpur University, Tezpur, 784028, Assam, India
| | - Sheetal Ramani
- Microbial Biotechnology and Protein Research Laboratory, Department of Molecular Biology and Biotechnology, School of Sciences, Tezpur University, Tezpur, 784028, Assam, India
| | - Surbhi Bhartari
- Microbial Biotechnology and Protein Research Laboratory, Department of Molecular Biology and Biotechnology, School of Sciences, Tezpur University, Tezpur, 784028, Assam, India
| | - Pronobesh Chattopadhyay
- Division of Pharmaceutical Technology, Defense Research Laboratory, Tezpur, 784501, Assam, India
| | - Ashis K Mukherjee
- Microbial Biotechnology and Protein Research Laboratory, Department of Molecular Biology and Biotechnology, School of Sciences, Tezpur University, Tezpur, 784028, Assam, India.
| |
Collapse
|
3
|
Keihanian F, Saeidinia A, Bagheri RK, Johnston TP, Sahebkar A. Curcumin, hemostasis, thrombosis, and coagulation. J Cell Physiol 2017; 233:4497-4511. [PMID: 29052850 DOI: 10.1002/jcp.26249] [Citation(s) in RCA: 89] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Revised: 10/11/2017] [Accepted: 10/18/2017] [Indexed: 12/15/2022]
Abstract
Atherothrombotic cardiovascular disease is a major cause of mortality throughout the world. Platelet activation and aggregation play a central role in hemostasis and thrombosis. Herbal medicines have been traditionally used in the management of cardiovascular disease and can help in modifying its progression, particularly in hemostasis and the coagulation process, as well as altering platelet function tests and some coagulation parameters. Curcumin is a polyphenol derived from the Curcuma longa plant and has been used extensively in complementary and alternative medicine, as it is nontoxic and safe with various therapeutic properties. Modern scientific research has demonstrated its anti-inflammatory, antioxidant, anti-carcinogenic, antithrombotic, and cardiovascular protective effects. The present study reviewed previous studies in the literature, which support the positive activity of curcumin in hemostasis, anticoagulation, and fibrinolysis. We also presented molecular mechanisms associated with the antiplatelet and anticoagulant activities of curcumin and potential implications for the treatment of cardiovascular disease.
Collapse
Affiliation(s)
- Faeze Keihanian
- Pharmaceutical Research Division, Booali Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.,Cardiology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Amin Saeidinia
- Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Ramin Khameneh Bagheri
- Cardiology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Thomas P Johnston
- Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri
| | - Amirhossein Sahebkar
- Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
4
|
Nguyen SD, Maaninka K, Lappalainen J, Nurmi K, Metso J, Öörni K, Navab M, Fogelman AM, Jauhiainen M, Lee-Rueckert M, Kovanen PT. Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties. Arterioscler Thromb Vasc Biol 2015; 36:274-84. [PMID: 26681753 PMCID: PMC4725095 DOI: 10.1161/atvbaha.115.306827] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2014] [Accepted: 11/18/2015] [Indexed: 01/10/2023]
Abstract
OBJECTIVE Apolipoprotein A-I (apoA-I) has been shown to possess several atheroprotective functions, including inhibition of inflammation. Protease-secreting activated mast cells reside in human atherosclerotic lesions. Here we investigated the effects of the neutral proteases released by activated mast cells on the anti-inflammatory properties of apoA-I. APPROACH AND RESULTS Activation of human mast cells triggered the release of granule-associated proteases chymase, tryptase, cathepsin G, carboxypeptidase A, and granzyme B. Among them, chymase cleaved apoA-I with the greatest efficiency and generated C-terminally truncated apoA-I, which failed to bind with high affinity to human coronary artery endothelial cells. In tumor necrosis factor-α-activated human coronary artery endothelial cells, the chymase-cleaved apoA-I was unable to suppress nuclear factor-κB-dependent upregulation of vascular cell adhesion molecule-1 (VCAM-1) and to block THP-1 cells from adhering to and transmigrating across the human coronary artery endothelial cells. Chymase-cleaved apoA-I also had an impaired ability to downregulate the expression of tumor necrosis factor-α, interleukin-1β, interleukin-6, and interleukin-8 in lipopolysaccharide-activated GM-CSF (granulocyte-macrophage colony-stimulating factor)- and M-CSF (macrophage colony-stimulating factor)-differentiated human macrophage foam cells and to inhibit reactive oxygen species formation in PMA (phorbol 12-myristate 13-acetate)-activated human neutrophils. Importantly, chymase-cleaved apoA-I showed reduced ability to inhibit lipopolysaccharide-induced inflammation in vivo in mice. Treatment with chymase blocked the ability of the apoA-I mimetic peptide L-4F, but not of the protease-resistant D-4F, to inhibit proinflammatory gene expression in activated human coronary artery endothelial cells and macrophage foam cells and to prevent reactive oxygen species formation in activated neutrophils. CONCLUSIONS The findings identify C-terminal cleavage of apoA-I by human mast cell chymase as a novel mechanism leading to loss of its anti-inflammatory functions. When targeting inflamed protease-rich atherosclerotic lesions with apoA-I, infusions of protease-resistant apoA-I might be the appropriate approach.
Collapse
Affiliation(s)
- Su Duy Nguyen
- From the Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (S.D.N., K.M., J.L., K.N., K.Ö., M.L.-R., P.T.K.); National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum Helsinki, Helsinki, Finland (J.M., M.J.); and Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (M.N., A.M.F.)
| | - Katariina Maaninka
- From the Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (S.D.N., K.M., J.L., K.N., K.Ö., M.L.-R., P.T.K.); National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum Helsinki, Helsinki, Finland (J.M., M.J.); and Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (M.N., A.M.F.)
| | - Jani Lappalainen
- From the Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (S.D.N., K.M., J.L., K.N., K.Ö., M.L.-R., P.T.K.); National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum Helsinki, Helsinki, Finland (J.M., M.J.); and Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (M.N., A.M.F.)
| | - Katariina Nurmi
- From the Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (S.D.N., K.M., J.L., K.N., K.Ö., M.L.-R., P.T.K.); National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum Helsinki, Helsinki, Finland (J.M., M.J.); and Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (M.N., A.M.F.)
| | - Jari Metso
- From the Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (S.D.N., K.M., J.L., K.N., K.Ö., M.L.-R., P.T.K.); National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum Helsinki, Helsinki, Finland (J.M., M.J.); and Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (M.N., A.M.F.)
| | - Katariina Öörni
- From the Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (S.D.N., K.M., J.L., K.N., K.Ö., M.L.-R., P.T.K.); National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum Helsinki, Helsinki, Finland (J.M., M.J.); and Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (M.N., A.M.F.)
| | - Mohamad Navab
- From the Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (S.D.N., K.M., J.L., K.N., K.Ö., M.L.-R., P.T.K.); National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum Helsinki, Helsinki, Finland (J.M., M.J.); and Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (M.N., A.M.F.)
| | - Alan M Fogelman
- From the Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (S.D.N., K.M., J.L., K.N., K.Ö., M.L.-R., P.T.K.); National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum Helsinki, Helsinki, Finland (J.M., M.J.); and Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (M.N., A.M.F.)
| | - Matti Jauhiainen
- From the Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (S.D.N., K.M., J.L., K.N., K.Ö., M.L.-R., P.T.K.); National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum Helsinki, Helsinki, Finland (J.M., M.J.); and Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (M.N., A.M.F.)
| | - Miriam Lee-Rueckert
- From the Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (S.D.N., K.M., J.L., K.N., K.Ö., M.L.-R., P.T.K.); National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum Helsinki, Helsinki, Finland (J.M., M.J.); and Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (M.N., A.M.F.)
| | - Petri T Kovanen
- From the Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (S.D.N., K.M., J.L., K.N., K.Ö., M.L.-R., P.T.K.); National Institute for Health and Welfare, Genomics and Biomarkers Unit, Biomedicum Helsinki, Helsinki, Finland (J.M., M.J.); and Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (M.N., A.M.F.).
| |
Collapse
|
5
|
Chen C, Yang FQ, Zhang Q, Wang FQ, Hu YJ, Xia ZN. Natural Products for Antithrombosis. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE : ECAM 2015; 2015:876426. [PMID: 26075003 PMCID: PMC4449941 DOI: 10.1155/2015/876426] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Revised: 03/22/2015] [Accepted: 03/24/2015] [Indexed: 12/25/2022]
Abstract
Thrombosis is considered to be closely related to several diseases such as atherosclerosis, ischemic heart disease and stroke, as well as rheumatoid arthritis, hyperuricemia, and various inflammatory conditions. More and more studies have been focused on understanding the mechanism of molecular and cellular basis of thrombus formation as well as preventing thrombosis for the treatment of thrombotic diseases. In reality, there is considerable interest in the role of natural products and their bioactive components in the prevention and treatment of thrombosis related disorders. This paper briefly describes the mechanisms of thrombus formation on three aspects, including coagulation system, platelet activation, and aggregation, and change of blood flow conditions. Furthermore, the natural products for antithrombosis by anticoagulation, antiplatelet aggregation, and fibrinolysis were summarized, respectively.
Collapse
Affiliation(s)
- Cen Chen
- School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400030, China
| | - Feng-Qing Yang
- School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400030, China
| | - Qian Zhang
- School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400030, China
| | - Feng-Qin Wang
- School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400030, China
| | - Yuan-Jia Hu
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau
| | - Zhi-Ning Xia
- School of Chemistry and Chemical Engineering, Chongqing University, Chongqing 400030, China
| |
Collapse
|
6
|
Zhang J, Ma G, Lv Z, Zhou Y, Wen C, Wu Y, Xu R. Targeted thrombolysis strategies for neuroprotective effect. Neural Regen Res 2014; 9:1316-22. [PMID: 25221585 PMCID: PMC4160859 DOI: 10.4103/1673-5374.137580] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/12/2014] [Indexed: 12/24/2022] Open
Abstract
Stroke is usually treated by systemic thrombolytic therapy if the patient presents within an appropriate time window. There is also widespread interest in the development of thrombolytic agents that can be used in cases of delayed presentation. Current agents that can be used in cases of delayed presentation of nerve damage by thrombus. Current systemic thrombolytic therapy is associated with adverse effects such as fibrinogenolysis and bleeding. In an attempt to increase the efficacy, safety, and specificity of thrombolytic therapy, a number of targeted thrombolytic agents have been studied in recent years. This review focuses on the concepts underlying targeted thrombolytic therapy and describes recent drug developments in this field.
Collapse
Affiliation(s)
- Junping Zhang
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Guoxing Ma
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Zhimin Lv
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Yu Zhou
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Chunguang Wen
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Yaqing Wu
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| | - Ruian Xu
- School of Biomedical Sciences, Huaqiao University & Engineering Research Center of Molicular Medicine, Ministry of Education, Xiamen, Fujian Province, China
| |
Collapse
|